What Is GHRP-6? Structure, Receptor and Literature

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

GHRP-6 is one of the oldest synthetic growth hormone secretagogues still in routine laboratory use, and it occupies an unusual position: it predates the discovery of the receptor it acts on. Understanding it means separating three things that catalogue entries tend to blur — the molecule, the receptor, and the breadth of activity that makes it a blunt pharmacological tool.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

The molecule

Property	Value
Sequence	His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
Length	6 residues
Non-natural residues	D-Trp at position 2, D-Phe at position 5
C-terminus	Amidated
Usual salt form	Acetate
Receptor	GHS-R1a (ghrelin receptor)

Two features of that sequence deserve attention. First, two of the six residues are D-amino acids. This is a deliberate design choice: D-residues resist the proteases that cleave L-peptide bonds, and they constrain conformation. It also has an analytical consequence, because a D-to-L substitution does not change molecular mass. Mass spectrometry alone cannot distinguish correctly synthesised GHRP-6 from a stereochemically wrong batch; chromatographic separation is what resolves that question.

Second, the molecule is tryptophan-rich, with two Trp residues out of six. Tryptophan and histidine are among the residues most susceptible to oxidation, and both are present here. That is the structural reason GHRP-6 is treated as a light- and oxidation-sensitive reagent rather than a robust one.

The receptor, discovered afterwards

The historical order is worth stating plainly. Peptides of this family were identified by their activity — they released growth hormone from pituitary tissue — years before the receptor responsible was cloned. The 1998 review by Bowers in Cellular and Molecular Life Sciences is written from inside that period and is the best single account of how the series was developed and what was known at the time.

The 1995 study by Lei and colleagues examined the signalling consequences in human pituitary somatotroph cells, reporting that GHRP-6 stimulated phosphatidylinositol turnover. That finding placed the peptide’s action on a Gq-coupled pathway, consistent with what was later established for GHS-R1a, and it is an example of mechanism being inferred from signalling before the receptor identity was settled.

The receptor subsequently turned out to be the target of an endogenous ligand, ghrelin. GHRP-6 is therefore best described as a synthetic agonist at a receptor whose natural ligand is a much larger, acylated peptide. The two are not analogues of one another in any structural sense.

Why “non-selective” is the operative word

Later secretagogues were explicitly characterised against GHRP-6 as the less selective comparator. The 2000 study by Papotti and colleagues in the Journal of Clinical Endocrinology and Metabolism is central here: it mapped growth hormone secretagogue binding sites across peripheral human tissues, demonstrating that binding is not confined to the pituitary.

For experimental design, the implication is specific:

An effect observed in a peripheral tissue preparation cannot be attributed to pituitary signalling by default.
Comparisons with a selective secretagogue are only interpretable if the readout distinguishes the pathways involved.
Negative controls matter more than usual, because the number of plausible sites of action is larger.

This is not a flaw so much as a property. A broadly acting agonist is the wrong tool for dissecting one pathway and a reasonable one for asking whether a tissue responds to secretagogue signalling at all.

What recent work has looked at

The modern literature on GHRP-6 has moved largely away from growth hormone release and towards cytoprotection. Three papers illustrate the direction:

Study	Model	Reported focus
Delgado-Rubín de Célix 2006	Glutamate excitotoxicity, neuronal	Survival factor activity
Berlanga-Acosta 2024	Doxorubicin cardiotoxicity, rodent	Prosurvival signalling
Zhao 2025	Acute kidney injury, hydrogel delivery	Metabolic regulation

The 2025 paper is methodologically the most interesting of the three for laboratory purposes, because it is a formulation study: the peptide is delivered from a hydrogel rather than in solution. Work of that kind is a useful source of information about how the molecule behaves in a matrix, which is rarely addressed in the pharmacology literature.

Handling consequences of the structure

The composition dictates the precautions. Two tryptophans and a histidine mean oxidation is the principal degradation route to worry about, and the published work on metal-catalysed histidine oxidation in model peptides applies directly. In practice:

Store the lyophilized powder sealed at −20 °C, protected from light. Amber vials or foil overwrap are not cosmetic for a Trp-rich peptide.
Avoid diluents and buffers with appreciable trace metal content, since metal ions catalyse oxidation at histidine and tryptophan.
Aliquot after reconstitution rather than returning one tube to the freezer repeatedly. See storing reconstituted peptides.
Calculate concentration from the net peptide mass, not the gross vial weight: the acetate counterion and residual water are both real mass. Our reconstitution calculator takes the figures from the certificate.

Our GHRP-6 research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.

Open questions

How much of the cytoprotective activity reported in recent models is GHS-R1a-dependent?
What are the peripheral binding sites identified in human tissue, at the molecular level?
Does the D-residue content measurably reduce degradation in serum-containing media relative to an all-L analogue?

Frequently asked questions

What is GHRP-6?

GHRP-6 is a synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, developed from work on growth hormone releasing peptides in the 1980s. It binds the growth hormone secretagogue receptor, now known as the ghrelin receptor GHS-R1a.

What does GHRP-6 acetate mean?

Acetate is the counterion. Peptides carrying basic residues are isolated as salts, and acetate is a common exchange product after purification. The acetate contributes mass that is not peptide, which matters when calculating a molar concentration from vial weight.

Is GHRP-6 the same as ghrelin?

No. Ghrelin is a 28-residue acylated peptide; GHRP-6 is a six-residue synthetic peptide. They converge on the same receptor, GHS-R1a, but differ in size, in the requirement for acylation, and in selectivity.

Why is GHRP-6 described as non-selective?

Beyond GHS-R1a, published work describes GHRP-6 binding sites in peripheral tissues, and effects that do not map cleanly onto a single receptor. That breadth is the main reason newer secretagogues were developed and characterised as selective by comparison.

What is the amidated C-terminus for?

The C-terminal lysine is amidated rather than left as a free acid. Amidation removes a negative charge and alters susceptibility to carboxypeptidases, and it is part of the molecule’s definition: a free-acid version is a different compound with a different mass.

References

Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998. PMID: 9893708 https://pubmed.ncbi.nlm.nih.gov/9893708/
Lei T, et al. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. J Mol Endocrinol. 1995. PMID: 7772238 https://pubmed.ncbi.nlm.nih.gov/7772238/
Papotti M, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000. PMID: 11061542 https://pubmed.ncbi.nlm.nih.gov/11061542/
Delgado-Rubín de Célix A, et al. Growth hormone releasing peptide-6 acts as a survival factor in glutamate-induced excitotoxicity. J Neurochem. 2006. PMID: 17076656 https://pubmed.ncbi.nlm.nih.gov/17076656/
Berlanga-Acosta J, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front Pharmacol. 2024. PMID: 38873418 https://pubmed.ncbi.nlm.nih.gov/38873418/
Zhao X, et al. Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. J Nanobiotechnology. 2025. PMID: 41327290 https://pubmed.ncbi.nlm.nih.gov/41327290/